Use of restaging bladder tumor resection for bladder cancer among medicare beneficiaries

Urology

Volumn 78, Issue 6, 2011, Pages 1345-1349

  Skolarus, Ted A ^a,b   Ye, Zaojun ^b   Montgomery, Jeffrey S ^a   Weizer, Alon Z ^a   Hafez, Khaled S ^a   Lee, Cheryl T ^a   Miller, David C ^a,c   Wood Jr , David P ^a   Montie, James E ^a,b   Hollenbeck, Brent K ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Dow Division of Health Services Research   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLADDER CANCER; BLADDER SURGERY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESTAGING BLADDER TUMOR RESECTION; THERAPY EFFECT;

AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICARE; NEOPLASM STAGING; SEER PROGRAM; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 82955233408     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.05.071     Document Type: Article

References (30)

1. C.L. Amling Diagnosis and management of superficial bladder cancer Curr Probl Cancer 25 4 2001 219 278
2. H.W. Herr Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome J Urol 163 1 2000 60 61 [Discussion:61-62]
3. NCCN Clinical Practice Guidelines Bladder Cancer Version 2 http://www.nccn.org/professionals/physician-gls/PDF/bladder.pdf 2010 Accessed August 2, 2010
4. C. Snyder, L. Harlan, and K. Knopf Patterns of care for the treatment of bladder cancer J Urol 169 5 2003 1697 1701
5. J.E. Montie, P.E. Clark, and M.A. Eisenberger Clinical Practice Guidelines in Oncology: Bladder Cancer J Natl Compr Cancer Netw 7 1 2009 8 39 http://www.nccn.org/professionals/physician-gls/PDF/bladder.pdf
6. S.C. Dutta, J.A. Smith Jr., and S.B. Shappell Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy J Urol 166 2 2001 490 493
7. D. Schrag, N. Mitra, and F. Xu Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population Urology 65 6 2005 1118 1125
8. A. Brauers, R. Buettner, and G. Jakse Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 165 3 2001 808 810
9. M. Schulze, N. Stotz, and J. Rassweiler Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach J Endourol 21 12 2007 1533 1541
10. H.W. Herr The value of a second transurethral resection in evaluating patients with bladder tumors J Urol 162 1 1999 74 76
11. M.A. Zurkirchen, T. Sulser, and A. Gaspert Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists Urol Int 72 2 2004 99 102
12. M.O. Grimm, C. Steinhoff, and X. Simon Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study J Urol 170 2 Pt. 1 2003 433 437
13. G. Dalbagni, H.W. Herr, and V.E. Reuter Impact of a second transurethral resection on the staging of T1 bladder cancer Urology 60 5 2002 822 824 [Discussion:824-825]
14. G. Dalbagni, K. Vora, and M. Kaag Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer Eur Urol 56 6 2009 903 910
15. H.W. Herr Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy J Urol 174 6 2005 2134 2137
16. R.T. Divrik, U. Yildirim, and F. Zorlu The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial J Urol 175 5 2006 1641 1644
17. J.L. Warren, C.N. Klabunde, and D. Schrag Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 Suppl 8 2002 IV-3 IV18
18. P.B. Bach, E. Guadagnoli, and D. Schrag Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations Med Care 40 Suppl 8 2002 IV-19 IV-25
19. B.K. Hollenbeck, Z. Ye, and R.L. Dunn Provider treatment intensity and outcomes for patients with early-stage bladder cancer J Natl Cancer Inst 101 8 2009 571 580
20. C.N. Klabunde, A.L. Potosky, and J.M. Legler Development of a comorbidity index using physician claims data J Clin Epidemiol 53 12 2000 1258 1267
21. A.V. Diez Roux, S.S. Merkin, and D. Arnett Neighborhood of residence and incidence of coronary heart disease N Engl J Med 345 2 2001 99 106
22. M.J. Radford, and J.M. Foody How do observational studies expand the evidence base for therapy? JAMA 286 10 2001 1228 1230
23. L.E. Braitman, and P.R. Rosenbaum Rare outcomes, common treatments: analytic strategies using propensity scores Ann Intern Med 137 8 2002 693 695
24. P.C. Austin, M.M. Mamdani, and T.A. Stukel The use of the propensity score for estimating treatment effects: administrative versus clinical data Stat Med 24 10 2005 1563 1578
25. H.W. Herr Transurethral resection of muscle-invasive bladder cancer: 10-year outcome J Clin Oncol 19 1 2001 89 93
26. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2 2008 303 314
27. Bladder Cancer Clinical Guideline Update Panel Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1, and Tis): 2007 update 2007 American Urological Association Education and Research, Inc Linthicum, MD
28. R.T. Divrik, A.F. Sahin, and U. Yildirim Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial Eur Urol 58 2 2010 185 190
29. Surveillance Epidemiology and End Results (SEER) Program Home page http://www.seer.cancer.gov/ Accessed February 1, 2011
30. D.F. Penson, P.C. Albertsen, and P.S. Nelson Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 93 23 2001 1822 1823